262 related articles for article (PubMed ID: 12571812)
41. The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
Fizazi K; John WJ; Vogelzang NJ
Semin Oncol; 2002 Feb; 29(1):77-81. PubMed ID: 11836672
[TBL] [Abstract][Full Text] [Related]
42. Emerging insights into the biology and therapy of malignant mesothelioma.
Vogelzang NJ
Semin Oncol; 2002 Dec; 29(6 Suppl 18):35-42. PubMed ID: 12571809
[TBL] [Abstract][Full Text] [Related]
43. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Adjei AA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
[TBL] [Abstract][Full Text] [Related]
44. Pemetrexed in gastric cancer.
Sobrero A; Caprioni F; Fornarini G; Mammoliti S; Comandini D; Baldo S; Decian F
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):51-5. PubMed ID: 15655938
[TBL] [Abstract][Full Text] [Related]
45. The potential role of pemetrexed in gastrointestinal cancer.
Meriggi F; Di Biasi B; Caliolo C; Zaniboni A
Chemotherapy; 2008; 54(1):1-8. PubMed ID: 18063861
[TBL] [Abstract][Full Text] [Related]
46. Antifolates in clinical development.
Takimoto CH
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-40-S18-51. PubMed ID: 9420020
[TBL] [Abstract][Full Text] [Related]
47. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis.
Spielmann M; Martin M; Namer M; duBois A; Unger C; Dodwell DJ
Clin Breast Cancer; 2001 Apr; 2(1):47-51. PubMed ID: 11899382
[TBL] [Abstract][Full Text] [Related]
48. Review of a promising new agent--pemetrexed disodium.
Paz-Ares L; Bezares S; Tabernero JM; Castellanos D; Cortes-Funes H
Cancer; 2003 Apr; 97(8 Suppl):2056-63. PubMed ID: 12673697
[TBL] [Abstract][Full Text] [Related]
49. Enter Alimta: a new generation antifolate.
Zhao R; Goldman ID
Oncologist; 2004; 9(3):242-4. PubMed ID: 15169978
[No Abstract] [Full Text] [Related]
50. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
[TBL] [Abstract][Full Text] [Related]
51. DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens.
Leon LG; Giovannetti E; Smid K; van Houte BP; Hanauske AR; Giaccone G; Peters GJ
Curr Drug Metab; 2011 Dec; 12(10):956-65. PubMed ID: 21787269
[TBL] [Abstract][Full Text] [Related]
52. Overview of phase I trials of multitargeted antifolate (MTA, LY231514).
Rinaldi DA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):82-8. PubMed ID: 10598560
[TBL] [Abstract][Full Text] [Related]
53. Preclinical and clinical studies with combinations of pemetrexed and gemcitabine.
Adjei AA
Semin Oncol; 2002 Dec; 29(6 Suppl 18):30-4. PubMed ID: 12571808
[TBL] [Abstract][Full Text] [Related]
54. Thymidylate synthase inhibitors.
Danenberg PV; Malli H; Swenson S
Semin Oncol; 1999 Dec; 26(6):621-31. PubMed ID: 10606255
[TBL] [Abstract][Full Text] [Related]
55. Antifolates: the next millennium.
Allegra CJ
Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-2. PubMed ID: 10598548
[No Abstract] [Full Text] [Related]
56. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
Budde LS; Hanna NH
Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
[TBL] [Abstract][Full Text] [Related]
57. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
[No Abstract] [Full Text] [Related]
58. Preclinical development of Alimta (Pemetrexed, LY231514), a multitargeted antifolate.
Schultz RM
Prog Drug Res; 2005; 63():275-300. PubMed ID: 16265884
[No Abstract] [Full Text] [Related]
59. Overview of phase II trials of MTA in solid tumors.
O'Dwyer PJ; Nelson K; Thornton DE
Semin Oncol; 1999 Apr; 26(2 Suppl 6):99-104. PubMed ID: 10598563
[TBL] [Abstract][Full Text] [Related]
60. Pemetrexed disodium, a novel antifolate with multiple targets.
Curtin NJ; Hughes AN
Lancet Oncol; 2001 May; 2(5):298-306. PubMed ID: 11905785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]